Cytel Announces East Alloy


Cytel Inc. has announced the launch of East Alloy. This new platform is a web-native extension of Cytel’s East software for adaptive clinical trial design and analysis. East Alloy enables implementation of computationally intensive Bayesian methods that may be otherwise impractical. The launch of East Alloy builds on Cytel’s time-tested record of delivering Bayesian tools and engines to the pharmaceutical industry for clinical trials. To support the launch, Cytel hosted a 60-minute webinar on July 29 introducing East Alloy and detailing how it can be used to adopt Bayesian and innovative methods with speed and confidence.

Amidst the rapid pace of modern clinical development, drug developers are increasingly seeking greater clinical trial efficiency and probability of success while also minimizing costs. This often means turning to sophisticated and innovative clinical trial designs, including Bayesian methods. However, underpowered on-premise technology can make execution of such methods challenging under routine statistical design timelines. Furthermore, publicly available solutions often rely on unverified bespoke coding, which can introduce risk to clinical programs.

“As trial designers turn to open-source or home-grown trial design solutions to meet the demands of modern drug development, they’re experiencing a range of challenges, from a lack of user-friendliness and quality control, to difficulty accessing the computational power needed to deploy these complex methods,” commented Yannis Jemiai, Chief Scientific Officer at Cytel. “With East Alloy, we’re combining Cytel-curated public solutions that we’ve subjected to our robust verification program with Cytel’s own cutting-edge engines, and then accelerating their delivery via SaaS and cloud computing. This enables our customers to avoid extensive IT infrastructure and confidently deploy powerful innovative techniques and Bayesian methods with ease.”

Bayesian methods are of growing interest to the drug development industry, as they allow clinical investigators to leverage historical trial data as well as learnings from new data as it accrues throughout a trial.

“Our longstanding dedication to adaptive Bayesian approaches means we’re perfectly placed to meet and exceed the growing innovation needs of the pharmaceutical sector,“ said Pantelis Vlachos, Director and Strategic Consultant at Cytel. “But it’s key to ensure our customers can practically implement this kind of innovation. East Alloy, reinforced by industry-leading verification, training, and support from Cytel experts, means users can sustainably adopt Bayesian designs to expedite clinical development and overcome uncertainty without compromising scientific rigor.”

As part of Cytel’s continued effort to share expert insights on utilizing adaptive trial designs and Bayesian methodologies, Pantelis Vlachos presented a free 60-minute webinar on July 29 titled, ‘Introducing East Alloy: Verified Innovation for Complex Methods’. Attendees of the webinar will gain a deeper understanding of the new East Alloy platform and will learn how it can be used to easily apply innovative techniques and conduct complex Bayesian and Frequentist study designs.

The release of East Alloy follows the launch of East Hosted in 2019, which brought Cytel’s East software into the cloud aiming to simplify the deployment of software updates, reduce on-premise IT burden, and ultimately broaden access to Cytel’s trusted trial design and analysis engines.

To register for the free webinar, visit:

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.